JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266155

Human ARF3 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ARF3 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 2 and 4 bp deletion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human ARF3 knockout HEK-293T cell line (AB266155)
  • Sanger seq

Unknown

Sanger Sequencing - Human ARF3 knockout HEK-293T cell line (AB266155)

Allele-2 : 1 bp insertion in exon 2.

Sanger Sequencing - Human ARF3 knockout HEK-293T cell line (AB266155)
  • Sanger seq

Unknown

Sanger Sequencing - Human ARF3 knockout HEK-293T cell line (AB266155)

Allele-1 : 4 bp deletion in exon 2

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 2 and 4 bp deletion in exon 2

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266155-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266155-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266155 Human ARF3 knockout HEK-293T cell line", "number":"AB266155-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266155-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266155-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266155 Human ARF3 knockout HEK-293T cell line", "number":"AB266155-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266155-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266155 Human ARF3 knockout HEK-293T cell line", "number":"AB266155-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266155-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266155 Human ARF3 knockout HEK-293T cell line", "number":"AB266155-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ARF3
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ADP-ribosylation factor 3 commonly known as ARF3 is a small GTP-binding protein with a mass of approximately 20 kDa. It belongs to the ARF family and is expressed in many tissues especially within cellular compartments that are highly dynamic including the Golgi apparatus and the cytoplasm. ARF3 functions by binding and hydrolyzing GTP which is an important function in regulating vesicular trafficking and membrane lipid metabolism.
Biological function summary

The functions performed by ARF3 revolve around the regulation of vesicle formation and trafficking within cells. It is critical in the formation of COPI-coated vesicles and is involved in the retrieval pathway of membrane proteins between the Golgi and endoplasmic reticulum. ARF3 interacts closely with proteins like coatomer and ARF-GEFs (guanine nucleotide exchange factors) to facilitate these processes. As part of its biological activity ARF3 affects the recruitment of various effector proteins necessary for the vesicular transport.

Pathways

ARF3 plays significant roles in the regulation of intracellular transport pathways and lipid signaling pathways. It interacts with proteins involved in the phosphatidylinositol signaling pathway influencing membrane dynamics and cell signaling. ARF3's function aligns it closely with proteins such as phosphatidylinositol 4-kinases which are key in modifying phosphoinositides that are essential for membrane trafficking and signal transduction.

Connections between ARF3 and pathological conditions like cancer and neurodegenerative diseases have been observed. Abnormal expression or mutation of ARF3 may lead to disruptions in membrane trafficking contributing to disease progression. ARF3 has shown links with proteins such as RAB proteins in the context of cancer as they collaboratively affect cellular processes relevant to tumor progression such as cellular migration and invasion.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com